HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $6

Benzinga · 2d ago
HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $6.